Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Ltd., commonly known as Sun Pharma, is a leading global pharmaceutical company headquartered in India. Established in 1993, the company has grown to become one of the largest specialty generic pharmaceutical manufacturers in the world, with a strong presence in North America, Europe, and emerging markets. Sun Pharma focuses on a diverse range of therapeutic areas, including cardiology, psychiatry, neurology, and dermatology. Its core products encompass a wide array of generic medications, specialty pharmaceuticals, and over-the-counter products, distinguished by their high quality and affordability. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of innovative therapies. With a commitment to research and development, Sun Pharma has positioned itself as a key player in the global pharmaceutical landscape, recognised for its excellence in manufacturing and a strong market presence.
DitchCarbon Score
How does Sun Pharmaceutical Industries's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sun Pharmaceutical Industries's score of 47 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sun Pharmaceutical Industries's reported carbon emissions
In 2024, Sun Pharmaceutical Industries reported total carbon emissions of approximately 728,729,320 kg CO2e, comprising 111,175,000 kg CO2e from Scope 1, 237,766,000 kg CO2e from Scope 2, and 379,788,320 kg CO2e from Scope 3 emissions. This represents a significant increase in emissions compared to previous years, with Scope 1 emissions rising from 122,306,000 kg CO2e in 2023 and Scope 2 emissions decreasing from 261,803,000 kg CO2e. The company has set ambitious climate commitments, aiming for a 35% reduction in both Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. This target reflects Sun Pharmaceutical's commitment to sustainability and reducing its carbon footprint in the pharmaceutical industry. Overall, Sun Pharmaceutical Industries is actively working towards enhancing its environmental performance while addressing the challenges of climate change through measurable reduction targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sun Pharmaceutical Industries is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
